厄立特里亚克伦医院严重孕产妇结局的决定因素:一个无与伦比的病例控制研究
1Departement of Family and Community Health, Ministry of Health Anseba Province, Keren, Anseba, Eritrea.
PloS one
|May 13, 2024
概括
厄立特里亚的严重孕产妇结局 (SMO) 与未参加产前护理,以前的剖腹产和离医疗机构的距离有关. 改善运输和推系统可以减少这些风险.
科学领域:
- 产科和妇科 产科和妇科
- 公共卫生 公共卫生
- 孕产妇健康 孕产妇健康
背景情况:
- 厄立特里亚面临着高的孕产妇死亡率,对严重孕产妇结局 (SMO) 决定因素的理解有限.
- 关于SMO风险因素的先前研究存在于发展中国家,但不是特别在厄立特里亚.
研究的目的:
- 确定Keren省推医院的妇女中严重的孕产妇结果 (SMO) 的关键决定因素.
主要方法:
- 一项基于设施的,无与伦比的病例控制研究于2018年1月至2020年12月在凯伦医院进行.
- 追溯数据收集使用了撒哈拉以南非洲母亲近乎失踪 (MNM) 工具,对701个SMO病例和1,402个对照进行了追溯数据收集.
- 使用SPSS版本-22.2.进行双变量和多变量逻辑回归分析.
主要成果:
- 与SMO独立相关的因素包括:没有参加产前护理 (ANC) 随访 (AOR:4.53),当前怀孕的剖腹产 (AOR:3.75),来自较低级别设施的转诊 (AOR:11.8),居住距离30公里以上 (AOR:2.97),贫血史 (AOR:2.36),以及之前的剖腹产 (AOR:3.49).
结论:
- 缺乏ANC跟进,当前的C-section,较低级别的设施转诊,距离,贫血史和之前的C-sections是SMO的重要风险因素.
- 提高运输,加强转诊协议,确保公平分配紧急产科设施对于减少SMO至关重要.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Hazard Ratio
115
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
115
Comparing the Survival Analysis of Two or More Groups
177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
Statistical Methods for Analyzing Epidemiological Data
363
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
363
Kaplan-Meier Approach
133
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
133
Censoring Survival Data
85
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
85


